The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2016

Filed:

Jan. 15, 2004
Applicants:

Jörg Stürzebecher, Erfurt, DE;

Torsten Steinmetzer, Jena, DE;

Andrea Schweinitz, Jena, DE;

Inventors:

Jörg Stürzebecher, Erfurt, DE;

Torsten Steinmetzer, Jena, DE;

Andrea Schweinitz, Jena, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A61K 31/33 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); C07K 5/072 (2006.01); A61K 31/198 (2006.01); A61K 31/401 (2006.01); A61K 31/435 (2006.01); A61K 47/48 (2006.01); C07K 5/062 (2006.01); C07K 5/065 (2006.01);
U.S. Cl.
CPC ...
C07K 5/06095 (2013.01); A61K 31/198 (2013.01); A61K 31/401 (2013.01); A61K 31/435 (2013.01); A61K 47/48215 (2013.01); C07K 5/0606 (2013.01); C07K 5/06034 (2013.01); C07K 5/06078 (2013.01);
Abstract

The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula IP4-P3-P2-P1  (I),where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.


Find Patent Forward Citations

Loading…